Skip to content

Menu

Home
Study Details
Device
Organization
Centers
Study Results
Contact

Study Details

Study Design

A pre-market, prospective, multicentre, single-arm study.

Patient Population

Patients with symptomatic severe aortic stenosis and high or extreme surgical risk

References:

Aidietis, Audrius et al. “30-Day and 1-Year Outcomes With HYDRA Self-Expanding Transcatheter Aortic Valve: The Hydra CE Study.” JACC. Cardiovascular interventions vol. 15,1 (2022): 93-104. doi:10.1016/j.jcin.2021.09.004
“Five-year Clinical and Hemodynamic Evaluation of Hydra THV in Patients with Severe Aortic Stenosis” Presented at PCR London Valves 2025 by Bajoras, Vilhelmas.

Disclaimer: Hydra Transcatheter Aortic Valve is manufactured by Vascular Innovations Co. Ltd. Thailand, an SMT group company. Hydra is a trademark of Vascular Innovations Co. Ltd. All trademarks are the property of their respective owners. This website provides general study information for research and educational purposes and is not a substitute for professional medical advice.

Scroll to Top